標(biāo)題: Titlebook: Development of Antibody-Based Therapeutics; Translational Consid Mohammad A. Tabrizi,Gadi G. Bornstein,Scott L. Kla Book 20121st edition Sp [打印本頁(yè)] 作者: mobility 時(shí)間: 2025-3-21 16:43
書(shū)目名稱Development of Antibody-Based Therapeutics影響因子(影響力)
書(shū)目名稱Development of Antibody-Based Therapeutics影響因子(影響力)學(xué)科排名
書(shū)目名稱Development of Antibody-Based Therapeutics網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Development of Antibody-Based Therapeutics網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Development of Antibody-Based Therapeutics被引頻次
書(shū)目名稱Development of Antibody-Based Therapeutics被引頻次學(xué)科排名
書(shū)目名稱Development of Antibody-Based Therapeutics年度引用
書(shū)目名稱Development of Antibody-Based Therapeutics年度引用學(xué)科排名
書(shū)目名稱Development of Antibody-Based Therapeutics讀者反饋
書(shū)目名稱Development of Antibody-Based Therapeutics讀者反饋學(xué)科排名
作者: audiologist 時(shí)間: 2025-3-21 23:00 作者: 試驗(yàn) 時(shí)間: 2025-3-22 01:30
Grundbegriffe des preu?ischen Wegerechtsth a diverse array of soluble or cell-associated target antigens. Much like traditional small molecule drugs, a major challenge during the development of antibody-based therapeutics is maintaining an effective information flow and translation of accumulated knowledge throughout the various developme作者: 熱烈的歡迎 時(shí)間: 2025-3-22 05:44 作者: 得罪人 時(shí)間: 2025-3-22 11:14
Die Bermutung der unvordenklichen ZeitStates. With the passing of time, new technological developments together with competition for finite markets have continually raised the bar for the specifications of newly introduced antibodies. Our intent in this review is to provide a historical perspective on the technologies that have generate作者: glucagon 時(shí)間: 2025-3-22 13:49
,Vormundschaftliche Armutsbek?mpfung,fects of antibody-based drugs. Advances in protein engineering technologies afforded investigators the ability to overcome problems associated with introducing foreign antibodies into humans. These efforts included antibody chimerization, humanization, and the more recent development of human antibo作者: glucagon 時(shí)間: 2025-3-22 18:47
,Vormundschaftliche Armutsbek?mpfung,–antigen complexes for drug candidate optimization and the design of clinical dosing strategies. For measuring the dissociation equilibrium constants of mAbs binding reversibly to antigens, two premier technologies are commonly used: Biacore surface plasmon resonance (SPR) and the solution-based kin作者: 外形 時(shí)間: 2025-3-22 22:54
https://doi.org/10.1007/978-3-8349-9876-7he earliest stages of the discovery process for antibody-based therapeutics. Selection of the adequate affinity for a functional antibody should allow achievement of the maximum therapeutic benefit at a dose associated with a manageable cost of goods and the intended route of administration. Applica作者: 有助于 時(shí)間: 2025-3-23 03:08 作者: Tonometry 時(shí)間: 2025-3-23 08:39
Grundfragen der Familientherapieeep understanding of both the biology and the pathology of disease is essential for target identification and validation. This knowledge enables the rationale design of antibody therapeutic attributes including mechanism of action (MOA), specificity, potency, isotype subclass, affinity, and half-lif作者: 不吉祥的女人 時(shí)間: 2025-3-23 12:34
https://doi.org/10.1007/978-3-642-82615-3y-based oncology drugs. Mouse tumor models represent a reasonable approach for exploring antibody biodistribution. In general, a number of factors such as molecular size, antibody dose, and the length of in vivo tumor exposure can influence antibody localization and tumor penetration. With a few exc作者: 宇宙你 時(shí)間: 2025-3-23 15:20 作者: Console 時(shí)間: 2025-3-23 19:24
Im Bereiche der rhythmischen Schwankungen,lved from a simple descriptive endeavor to an essential component of model-based drug development. The role of PK/PD modeling can be more critical for antibody-based therapeutics owing to their complex pharmacological properties. Nonlinear behavior can manifest in most of the physiological processes作者: Subdue 時(shí)間: 2025-3-23 23:32
Grundgedanken der Lean Production few decades. The development of antibody-based therapeutics has benefited substantially from the utilization of population approaches. Moreover, almost all FDA-approved monoclonal antibody therapeutics have been evaluated using population approaches. In this chapter, application of population PK-PD作者: interrupt 時(shí)間: 2025-3-24 04:16 作者: 正式通知 時(shí)間: 2025-3-24 06:34 作者: Obverse 時(shí)間: 2025-3-24 12:38
Grundgesetz und Interessenverb?ndentinues to grow, development of robust manufacturing processes has been a significant focus within the pharmaceutical industry. This chapter describes the work-processes, challenges, and opportunities for platform production of antibodies with a focus on production for use in human clinical trials a作者: STENT 時(shí)間: 2025-3-24 18:03
Grundgesetz und sozialer Wandel, growth of the biologics market. As next generation modalities confront their first-generation rivals, it is critical that next generation products present a clear differentiating advantage over the existing competition and hence offer the potential to displace their first-generation rivals based on作者: SOW 時(shí)間: 2025-3-24 22:45
Grundkurs Algorithmen und Datenstrukturenst several years, several published reports have suggested that gamma globulin immune complexes may inhibit pathways of platelet destruction in ITP, attenuating thrombocytopenia in human patients and in animal models of ITP. This chapter reviews the literature associated with the use of immune compl作者: creatine-kinase 時(shí)間: 2025-3-24 23:51
https://doi.org/10.1007/978-3-322-94256-2riety of antigen targets. Knowledge of the structure–activity relationships for antibody-based modalities has provided the opportunity to generate highly tailored therapeutics by fine-tuning their pharmacological properties. As more advanced antibody-based modalities are emerging, implementation of 作者: 規(guī)范就好 時(shí)間: 2025-3-25 03:40 作者: ZEST 時(shí)間: 2025-3-25 07:34 作者: Meander 時(shí)間: 2025-3-25 15:05
https://doi.org/10.1007/978-1-4419-5955-3Antibody; Antibody-Based; Bornstein; Considerations; Development; Klakamp; Tabrizi; Therepeutic; Translation作者: 起波瀾 時(shí)間: 2025-3-25 17:08
978-1-4899-9113-3Springer Science+Business Media, LLC, part of Springer Nature 2012作者: 歡呼 時(shí)間: 2025-3-25 21:58 作者: 無(wú)思維能力 時(shí)間: 2025-3-26 00:38
Grundgesetz und Interessenverb?ndentinues to grow, development of robust manufacturing processes has been a significant focus within the pharmaceutical industry. This chapter describes the work-processes, challenges, and opportunities for platform production of antibodies with a focus on production for use in human clinical trials and marketing applications.作者: bile648 時(shí)間: 2025-3-26 06:59
Translational Strategies for Development of Antibody-Based Therapeutics: An Overview,th a diverse array of soluble or cell-associated target antigens. Much like traditional small molecule drugs, a major challenge during the development of antibody-based therapeutics is maintaining an effective information flow and translation of accumulated knowledge throughout the various developme作者: 品牌 時(shí)間: 2025-3-26 09:59 作者: detach 時(shí)間: 2025-3-26 15:28
Technologies for the Generation of Human Antibodies,States. With the passing of time, new technological developments together with competition for finite markets have continually raised the bar for the specifications of newly introduced antibodies. Our intent in this review is to provide a historical perspective on the technologies that have generate作者: white-matter 時(shí)間: 2025-3-26 19:20
Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutifects of antibody-based drugs. Advances in protein engineering technologies afforded investigators the ability to overcome problems associated with introducing foreign antibodies into humans. These efforts included antibody chimerization, humanization, and the more recent development of human antibo作者: 提升 時(shí)間: 2025-3-26 22:14
Biophysical Considerations for Development of Antibody-Based Therapeutics,–antigen complexes for drug candidate optimization and the design of clinical dosing strategies. For measuring the dissociation equilibrium constants of mAbs binding reversibly to antigens, two premier technologies are commonly used: Biacore surface plasmon resonance (SPR) and the solution-based kin作者: 大看臺(tái) 時(shí)間: 2025-3-27 02:07 作者: V洗浴 時(shí)間: 2025-3-27 05:46
Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Ifor successful translation of information into the later phases of antibody development require the use of relevant bioanalytical (BA) methodologies from early preclinical stages. Here, we discuss a suite of BA methodologies that can be used to enable pharmacokinetics, immunogenicity, and biomarker 作者: 伴隨而來(lái) 時(shí)間: 2025-3-27 10:56 作者: disciplined 時(shí)間: 2025-3-27 16:09 作者: 2否定 時(shí)間: 2025-3-27 19:24 作者: Fibrillation 時(shí)間: 2025-3-28 00:17
Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Theraplved from a simple descriptive endeavor to an essential component of model-based drug development. The role of PK/PD modeling can be more critical for antibody-based therapeutics owing to their complex pharmacological properties. Nonlinear behavior can manifest in most of the physiological processes作者: Respond 時(shí)間: 2025-3-28 03:26
Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational few decades. The development of antibody-based therapeutics has benefited substantially from the utilization of population approaches. Moreover, almost all FDA-approved monoclonal antibody therapeutics have been evaluated using population approaches. In this chapter, application of population PK-PD作者: febrile 時(shí)間: 2025-3-28 08:38
Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics,f relevant biomarkers can streamline this process significantly. Selecting and evaluating relevant biomarkers early on not only lessens the time and cost associated with clinical evaluation, but also fosters implementation of rational decision-making processes throughout various antibody development作者: Pedagogy 時(shí)間: 2025-3-28 11:51 作者: 縱欲 時(shí)間: 2025-3-28 15:40
Considerations in Manufacturing Process Development for Antibody-Based Therapeutics,ntinues to grow, development of robust manufacturing processes has been a significant focus within the pharmaceutical industry. This chapter describes the work-processes, challenges, and opportunities for platform production of antibodies with a focus on production for use in human clinical trials a作者: 圍巾 時(shí)間: 2025-3-28 18:45
Strategies for Development of Next Generation Antibody-Based Therapeutics, growth of the biologics market. As next generation modalities confront their first-generation rivals, it is critical that next generation products present a clear differentiating advantage over the existing competition and hence offer the potential to displace their first-generation rivals based on作者: AGGER 時(shí)間: 2025-3-29 01:44
Immune Complex Therapies for Treatment of Immune Thrombocytopenia,st several years, several published reports have suggested that gamma globulin immune complexes may inhibit pathways of platelet destruction in ITP, attenuating thrombocytopenia in human patients and in animal models of ITP. This chapter reviews the literature associated with the use of immune compl作者: Living-Will 時(shí)間: 2025-3-29 07:09 作者: 最高點(diǎn) 時(shí)間: 2025-3-29 10:59
Application of Bioinformatics Principles for Target Evaluation,作者: SLUMP 時(shí)間: 2025-3-29 12:11 作者: 觀察 時(shí)間: 2025-3-29 19:25
Im Bereiche der rhythmischen Schwankungen,, and linking PK/PD relationships to clinical outcomes. To improve prospective model predictions of drug efficacy and safety, new approaches will be needed to link antibody disposition with robust systems pharmacology models of drug and disease mechanisms.作者: Communal 時(shí)間: 2025-3-29 22:59 作者: temperate 時(shí)間: 2025-3-30 02:31 作者: Obstreperous 時(shí)間: 2025-3-30 04:09
Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therap, and linking PK/PD relationships to clinical outcomes. To improve prospective model predictions of drug efficacy and safety, new approaches will be needed to link antibody disposition with robust systems pharmacology models of drug and disease mechanisms.作者: 等級(jí)的上升 時(shí)間: 2025-3-30 10:35 作者: dithiolethione 時(shí)間: 2025-3-30 14:30 作者: deriver 時(shí)間: 2025-3-30 17:19
,Grundgefühle — Ein Neues Paradigma?,nto large Phase 3 clinical trials. CSF phospho-tau andtotal tau are also promising biomarkers for therapies that target either Aβ or tau. Volumetric MRI and FDG–PET require further studies before they can be considered biomarkers indicative of response to AD disease modifiers.作者: Observe 時(shí)間: 2025-3-30 21:17 作者: Mortar 時(shí)間: 2025-3-31 02:58
Grundkurs Algorithmen und Datenstrukturensed for the effects of immune complexes in ITP, possible adverse effects associated with immune complexes, and translational considerations for the development of novel immune complex therapies (e.g., antibody-coated liposomes).作者: ALTER 時(shí)間: 2025-3-31 06:15
Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeuticsrties and biodistribution, antigen turnover rate, and antigen concentrations under physiological and pathological conditions can facilitate determination of the optimum affinity required. This chapter will review the critical considerations necessary for the design of optimum affinity goals for antibody-based therapeutics.作者: insipid 時(shí)間: 2025-3-31 11:28
,Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics,nto large Phase 3 clinical trials. CSF phospho-tau andtotal tau are also promising biomarkers for therapies that target either Aβ or tau. Volumetric MRI and FDG–PET require further studies before they can be considered biomarkers indicative of response to AD disease modifiers.作者: 胰臟 時(shí)間: 2025-3-31 14:06
Strategies for Development of Next Generation Antibody-Based Therapeutics,rthologous cognate antigens), binding epitopes, pharmacokinetics, and potency offer critical differentiating characteristics for next generation antibody-based therapeutics. Herein we discuss recent approaches employed for development of next generation antibody-based therapeutics.作者: hypnotic 時(shí)間: 2025-3-31 17:55
Immune Complex Therapies for Treatment of Immune Thrombocytopenia,sed for the effects of immune complexes in ITP, possible adverse effects associated with immune complexes, and translational considerations for the development of novel immune complex therapies (e.g., antibody-coated liposomes).
